INTRODUCTION
Leprechaunism is a rare genetic disorder characterized by physical abnormalities, intrauterine and neonatal growth retardation, poorly developed subcutaneous fat and muscle at birth, and early death; it is frequently associated with hyperinsulinemia and insulin resistance [reviewed in (1) ]. In previous studies with skin fibroblasts established in culture from a patient with typical features ofthe disorder, we have demonstrated a profound decrease in 1251-labeled insulin binding to insulin receptors (2) and a profound impairment of insulin's ability to stimulate glucose incorporation in the patient's cells (3) . In other patients with leprechaunism, insulin binding is normal and tissue resistance to insulin is thought to reflect a postreceptor defect (4, 5) .
In an attempt to demonstrate the specificity of the defect in insulin binding and of the insulin biological effect in our patient, we also examined the ability ofthe insulinlike growth factor (IGF),1 multiplication-stimulating activity (MSA), to stimulate glucose incorporation in patient's and control fibroblasts. The IGF are polypeptides chemically related to insulin (6, 7) that exhibit a spectrum of biological activities similar to insulin, acting through IGF receptors or insulin receptors (6, 8, 9) . MSA, purified from rat liver cell culture medium (10) , interacts with receptors for IGF-I and IGF-II, the two IGF isolated from human plasma whose amino acid sequences have been determined (11) .2 MSA stimulated glucose incorporation in normal fibroblasts with a high potency that suggested that it acted through an IGF receptor rather than an insulin receptor (3) . Surprisingly, stimulation of glucose incorporation by MSA also was impaired in the patient's fibroblasts (3) . This suggested the possibility that the lesion in the leprechaun patient's cells affected both insulin receptors and IGF receptors. In the present study, we demonstrate that 125I labeled IGF-I binding to the IGF-I receptor in fibroblasts from the leprechaun patient is decreased by >70%. Studies are presented to characterize the nature of this binding defect.
METHODS
Peptides. IGF-I and IGF-II were purified from human plasma as described (15) . The IGF-I preparation used for these experiments (16SPII) contained -10% contamination by IGF-II. A partially purified preparation (1932) of IGF-I and IGF-II (designated NSILA, nonsuppressible insulinlike activity) having one-eighth the specific activity of IGF-I in stimulating glucose oxidation (36 mU/mg), and one-fifth the potency of IGF-I in inhibiting 125I-labeled IGF-I binding to human fibroblasts (unpublished results) was used to determine nonspecific binding. IGF-II was from batch 9SEIV. Epidermal growth factor (EGF) purified from the submaxillary gland of male mice according to the procedures of Savage et al. (16) was a kind gift of Wayne B. Anderson, National Cancer Institute.
MSA was purified from serum-free medium conditioned by BRL 3A cells by Dowex 50 chromatography, Sephadex G-75 gel filtration, and preparative acrylamide electrophoresis as previously described (17) . The properties of Sephadex G-75 peak II MSA (mol wt 8,700) and MSA III-2 (mol wt 7,100) have been described previously (17, 18 IGF-I binding to fibroblasts in suspension. 125I-labeled IGF-I was prepared by a modified chloramine T procedure (20) . To 1 jig of IGF-I in 20 ,ul of Krebs-Ringer phosphate buffer, pH 7.5, was added -2 mCi of high concentration of carrier-free '251-sodium. The reaction was initiated by addition of 333 ,ug of chloramine T in 10 ,ul of H20, allowed to proceed for 20 s, and quenched with 100 ,ul of 1 M acetic acid-i mg/ml bovine serum albumin. The reaction mixture was fractionated immediately on Sephadex G-75 (1 cm x 50 cm, 1 M acetic acid-i mg/ml bovine serum albumin), and the fractions corresponding to the 125I-IGF-I peak stored at -200C for 2-4 wk. For some experiments, iodinated IGF-I was further purified by gel filtration on Sephadex G-25 (PD-10) in Hepes binding buffer immediately before use. The specific radioactivity of the seven 1251-labeled IGF-I preparations used for these experiments was 11-144 Ci/g.
Binding studies were performed as previously described (2, 19, 20 Eight paired experiments (patient/control) also were simultaneously analyzed using the LIGAND program (21) . For this analysis, in addition to the assumptions stated above, the binding capacity Ro was constrained to be the same for patient and control in a given experimental pair, but was allowed to vary between experiments.
EGF binding to fibroblasts. EGF was labeled with 1251_ labeled iodine by the chloramine-T procedure (22) and was purified on Sephadex G-25 (PD-10) immediately before use.
Specific radioactivities were 53-68 Ci/g.
Binding assay conditions were modified from Carpenter and Cohen (22) . Fibroblasts were plated at a density of 400,000-500,000 cells/well in Linbro 6-well, 35 7.5) and incubated at 37°C for the indicated times. At the end of the incubation, the medium was aspirated, the plates washed thoroughly, and cells solubilized with 0.1% sodium dodecyl sulfate-0.5 mM EDTA as previously described (2) . All points were determined in duplicate or triplicate. Cell number was determined on replicate wells after trypsinization.
RESULTS
Properties of the IGF-I receptor in normal human fibroblasts. 125I-labeled IGF-I bound rapidly to human fibroblasts at 15°C. Half-maximal binding was observed in -30 min; a steady state of binding occurred from 3-5 h of incubation (results not shown). At steady state, -85% of the total bound radioactivity was specific or saturable binding; that is, it was abolished by incubation with excess unlabeled NSILA. 125I_ labeled IGF-I remaining in the supernatant media after 3 h of incubation was physically intact as determined by Sephadex G-75 gel filtration in 1 M acetic acid (results not shown).
125I-labeled IGF-I bound to human fibroblasts at steady state dissociated rapidly when cells were sedimented; resuspended in Hepes binding buffer, and incubated at 37°C (Fig. 1 ). Approximately 50% of the radioactivity dissociated in 40 min, and 85% was dissociated by 5 h. Gel filtration (Sephadex G-75, 1 M acetic acid) of radioactivity released after 5 h of incubation indicated no conversion to lower molecular weight forms, although -20% of the radioactivity appeared in the excluded column volume (results not shown). Thus, release of bound IGF-I does not appear to involve degradation of the polypeptide.
Binding of tracer concentrations of 125I-labeled IGF-I to normal fibroblasts at 15°C was inhibited by unlabeled IGF-I in dose-dependent fashion. In 18 experiments, specific binding was 5.7+±0.5% (SEM) of input radioactivity/106 cells. Half-maximal inhibition occurred with 12.3±+ 1.5 (SEM) ng/ml of IGF-I.3 Partially purified NSILA was 21% as potent as IGF-I (data not shown).
The specificity of the IGF-I receptor was established 3This dose-response curve is somewhat less sensitive than was previously reported (11) (half-maximal binding at -4 ng/ml) with a different preparation of IGF-I and a slightly (Fig. 2) .
The decreased binding to the patient's fibroblasts appears to be an intrinsic property of the cells, rather than a result of the binding assay conditions. (a) 1251-labeled IGF-I recovered from the supernatant media after incubation with patient's cells and examined by gel filtration on Sephadex G-75 in 1 M acetic acid remained physically intact (results not shown), which suggests that the low binding to patient's fibroblasts did not result from degradation of the tracer.
(b) 125I-labeled IGF-I (0.25 ng/ml) bound rapidly to both patient's and control fibroblasts at 15°C. Maximal binding was observed by 2 (Table IV) . The iodinated peptide was added at concentrations of 50 or 100 pg/ml, concentrations that did not decrease the bound EGF/free EGF ratio (data not shown). Maximum binding to patient's fibroblasts compared to control fibroblasts was 87±49% (expressed per culture well) and 95±14% (expressed per cell). The doseresponse curves for EGF binding to patient's and control fibroblasts did not differ significantly (Fig. 3) . We conclude that the defect in the patient's fibroblast does not affect EGF binding.
Quantitative analysis of IGF-I competitive binding data. The eight paired IGF-I dose-response curves obtained in competitive binding experiments and For each experiment, 0.4-0.5 x 10 fibroblasts were plated in 35-mm multiwell tissue culture plates in growth medium and incubated at 37'C. Binding assays were performed 2 d later as described in Methods. Incubations were at 37'C in 10 mM NH4Cl with a tracer mass of 100 pg/ml for experiments 07, 08, and 09; and 50 pg/ml for experiments 11, 12, and 13. Total 125I-EGF bound (%) is compared per cell and per 35-mm culture well in patient's and control fibroblasts. The exceptionally high binding to control fibroblasts (expressed per 106 cells) in experiment 11 resulted, in part, from incomplete trypsinization resulting in an underestimate of cell number. Although in most experiments the cell number/well recovered at the end of the experiment was somewhat lower than the number of cells plated, the efficiency of plating for patient's and control fibroblasts appears to be similar.
concentration was the same for patient and control in a given experiment, allowing for variation from experiment to experiment. The results are plotted in Fig. 4 which Ka was constant for patient and control, and receptor concentration was allowed to vary (not shown). Thus, these results suggest that the decreased IGF-I binding to the patient's fibroblasts results from a decreased affinity for IGF-I.
The apparent decrease in Ka for IGF-I might have resulted from a decrease in the association rate con- (Table II) (Table II) were simultaneously fit for the patient's and control fibroblasts using the LIGAND program. A single class ofbinding sites was assumed.
Receptor number was assumed to be constant for patient and control fibroblasts in a given experiment, but allowed to vary from experiment to experiment. The composite fit was kindly performed by Dr. Peter Munson, NICHHD. Results of the eight paired competitive binding experiments presented in Table II were analyzed. Each dose-response curve was fit separately to a single site model using the LIGAND program (21).
stant, ka, or an increase in the dissociation rate constant, kd. When 1251-labeled IGF-I was bound to patient's and control fibroblasts at 15°C, the dissociation at 15°C following resuspension in medium without tracer was slow (<30% in 6 h, results not shown). Dissociation at 37°C was more rapid and complete, and was indistinguishable for control and patient's fibroblasts (Fig. 1) . blasts were compared (Fig. 5 In summary, we have demonstrated four defects in fibroblasts from this patient with leprechaunism: (a) impaired insulin binding to insulin receptors, (b )reduced affinity of the IGF-I receptor for IGF and MSA, (c) decreased stimulation of glucose incorporation by insulin via insulin receptors, and (d) decreased stimulation ofglucose incorporation by MSA via IGF receptors. Although these defects may have separate molecular and genetic bases, the possibility that these phenomena may be related also should be considered.
Several independent observations suggest possible relationships between insulin and IGF receptors, and their coupling to biological responses. (a) Human fibroblast insulin receptors (19, 20) and IGF-I receptors (Table I) interact with the same peptides (insulin, proinsulin, and the insulinlike growth factors), which suggests similarities in the two binding sites. (b) 1251-labeled IGF-I incubated with human fibroblasts (25, 26) and covalently crosslinked with disuccinimidyl suberate forms an IGF-I: receptor complex with the specificity of an IGF-I receptor, but with subunit size (mol wt 130,000 reduced) and aggregation properties (mol wt > 300,000, without reduction) indistinguishable from those of an insulin receptor. The subunit of mol wt 130,000 may contain both insulin and IGF-I binding sites, or, alternatively, the binding sites for the two hormones may be on separate but similar molecules. (c) In the leprechaun patient's fibroblasts, insulin receptor-mediated and IGF receptor-mediated glucose incorporation are impaired, whereas insulin receptormediated and IGF receptor-mediated amino acid transport are spared (3). This led us to propose that the two receptors use common mechanisms of coupling to different effector pathways and that the lesion in the patient's cells might affect a common coupling component closely linked to both insulin and IGF binding sites. (d) In rat adipocytes, physiological concentrations of insulin acting through insulin receptors increases the affinity of the adipocyte MSA receptor for MSA (27) . If similar interactions were to occur in other cell types, they would provide a mechanism by which a primary defect in the insulin receptor might affect the binding affinity of an IGF receptor.
It remains to be determined whether IGF-I receptors are affected in other patients with leprechaunism. These patients exhibit considerable heterogeneity in the apparent mechanisms for insulin resistance. In our patient (1-3) and one other (28), a primary cellular defect of insulin binding has been described. In other patients, defective insulin binding in circulating cells (which suggests a secondary defect) or normal insulin binding but defective responsiveness to insulin (which suggests a postreceptor defect) have been reported (4, 5, 29) . Identification of an IGF-I receptor defect in our patient's fibroblasts reopens the question whether some of the clinical manifestations of leprechaunism (especially intrauterine and neonatal growth retardation, poorly developed muscles, and absent fat) might result from a deficiency of IGF biological effect mediated through the IGF receptor.
